ROMA; Risk of Ovarian Malignancy Algorithm – BC273
♀️ Ovarian Cancer Risk Assessment
₹3299
MRP ₹3400
Sample Time: 4:30 PM
Report: 2nd Working Day
Sample Type: Blood (Serum)
Test Code: BC273
Report: 2nd Working Day
Sample Type: Blood (Serum)
Test Code: BC273
About this Test:
The Risk of Ovarian Malignancy Algorithm (ROMA) is an advanced diagnostic tool that combines the results of two blood tests (CA-125 and HE4) with a woman's menopausal status. It calculates a numerical score that helps predict the risk of a pelvic mass being malignant (cancerous).
✔ A powerful tool to help differentiate between a benign and a malignant ovarian mass before surgery.
✔ Helps in triaging high-risk patients to a specialized gynecologic oncologist for optimal care.
✔ More accurate than using the CA-125 test alone.
✔ A simple, non-invasive blood test.
The Risk of Ovarian Malignancy Algorithm (ROMA) is an advanced diagnostic tool that combines the results of two blood tests (CA-125 and HE4) with a woman's menopausal status. It calculates a numerical score that helps predict the risk of a pelvic mass being malignant (cancerous).
✔ A powerful tool to help differentiate between a benign and a malignant ovarian mass before surgery.
✔ Helps in triaging high-risk patients to a specialized gynecologic oncologist for optimal care.
✔ More accurate than using the CA-125 test alone.
✔ A simple, non-invasive blood test.
ROMA: Enhancing the Prediction of Ovarian Cancer
When an ultrasound or other imaging reveals a pelvic mass, the most urgent question is whether it is benign or malignant. The traditional tumor marker, CA-125, has limitations as it can be elevated in many non-cancerous conditions. The ROMA test was developed to provide a more accurate risk assessment.
The Components of the ROMA Score
The power of ROMA lies in its multi-faceted approach, combining three key pieces of information:
- CA-125: The conventional ovarian cancer marker. While useful, it can be elevated in benign conditions like endometriosis, fibroids, and pelvic inflammatory disease.
- HE4 (Human Epididymis Protein 4): A newer, more specific tumor marker for ovarian cancer. HE4 is less likely to be elevated in benign gynecological conditions, making it a valuable addition to CA-125.
- Menopausal Status: The risk of ovarian cancer increases significantly after menopause. The algorithm uses separate calculations for pre-menopausal and post-menopausal women to provide a more accurate risk score.
By integrating these three factors, the ROMA algorithm generates a single, predictive score indicating the likelihood of malignancy. This helps the surgeon and patient make more informed decisions about the type and extent of surgery needed, and whether a referral to a cancer specialist is required before the procedure.
Frequently Asked Questions (FAQ)
Q1: Why did my doctor order the ROMA test?
Your doctor likely ordered this test because an imaging scan (like an ultrasound) showed a mass on your ovary or in your pelvis. The ROMA test helps assess the risk that this mass is cancerous, which guides decisions about surgery and referral to a specialist.
Your doctor likely ordered this test because an imaging scan (like an ultrasound) showed a mass on your ovary or in your pelvis. The ROMA test helps assess the risk that this mass is cancerous, which guides decisions about surgery and referral to a specialist.
Q2: Does a high ROMA score mean I have ovarian cancer?
No. The ROMA test is a risk assessment tool, not a definitive diagnosis. A high score means there is a higher probability that the mass is malignant, and it indicates that you should be managed by a gynecologic oncologist. A biopsy taken during surgery is the only way to confirm a cancer diagnosis.
No. The ROMA test is a risk assessment tool, not a definitive diagnosis. A high score means there is a higher probability that the mass is malignant, and it indicates that you should be managed by a gynecologic oncologist. A biopsy taken during surgery is the only way to confirm a cancer diagnosis.
Q3: What are CA-125 and HE4?
CA-125 and HE4 are both proteins that can be elevated in the blood of women with ovarian cancer. They are used as "tumor markers." HE4 is generally considered more specific for ovarian cancer than CA-125, and using them together in the ROMA score provides the best predictive accuracy.
CA-125 and HE4 are both proteins that can be elevated in the blood of women with ovarian cancer. They are used as "tumor markers." HE4 is generally considered more specific for ovarian cancer than CA-125, and using them together in the ROMA score provides the best predictive accuracy.
Q4: Do I need to fast before this test?
No, fasting is not generally required for the ROMA test, which involves CA-125 and HE4 measurements.
No, fasting is not generally required for the ROMA test, which involves CA-125 and HE4 measurements.